Ultragenyx Pharma Offers Interim Data from Phase 3 Extension Study of Sialic Acid ER at Int'l Congress of World Muscle Safety
October 13, 2014 at 09:03 AM EDT
Ultragenyx Pharmaceutical Inc. (Nasdaq: RARE), a biopharmaceutical company focused on the development of novel products for rare and ...
